PUBLIC COMPANY
save$CRSPCRISPR Therapeutics AG
$CRSP51.42-5.23%Zug, CHupdated 17d ago
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom.
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension
- phase1A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
- phase1A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- phase2Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
- —A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
- phase1A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
- phase2A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
- phase2A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
🐶 Hiring Signal
News
- Seawolf surfaces with $100M, $1.2B Sanofi pact for redosable DNA medicinesBacked by Novartis’ venture arm, Eli Lilly and CRISPR Therapeutics, Seawolf is advancing its nonviral DNA delivery platform while inking a pact with Sanofi.biospace · 1d ago
- Big-name investors pour $100M into DNA therapeutics developer SeawolfThe startup, which also just disclosed an up to $1.2 billion partnership with Sanofi, is backed by Versant, MPM BioImpact, Eli Lilly and Novartis’ venture arm.biopharma_dive · 1d ago
- Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earningsWhen Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market.biospace · 3d ago
- This week in charts: Brain drugs are back on venture capitalists’ mindsFive neurology-focused startups have together raised around $450 million in the last few weeks. Elsewhere, investors had a muted response to the latest cell therapy research.biopharma_dive · 3d ago
- Big Pharma-backed Seawolf surfaces with $100M to hand, $1.2B Sanofi DNA med pactSeawolf Therapeutics has emerged from the deep with $100 million to fuel its DNA therapeutic ambitions and a billion-dollar deal with Sanofi.fiercebiotech · 4d ago
- Beam’s base editing therapy for sickle cell hits goal in pivotal trialThe result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.biopharma_dive · 6d ago
- Beam preps FDA run for industry-first base-edited therapy after pivotal sickle cell successBeam Therapeutics' risto-cel provided at least 12 consecutive months of freedom from severe pain crises for patients with sickle cell disease in a mid-stage trial, setting the stage for an FDA appl…biospace · 6d ago
- Beam’s sickle cell therapy results tee up potential Casgevy, Lyfgenia showdownGearing up for a potential FDA filing by the end of the year, Beam Therapeutics revealed results from a phase 1/2 study of its base-edited cell therapy risto-cel, showing the potential sickle cell…fiercebiotech · 6d ago
- Plug-and-play gene therapy: FDA executes on vision that’s been in the works for yearsFormer biologics boss Peter Marks had a vision. With the FDA’s latest draft guidance, it’s coming to fruition. Speaking with BioSpace, current CBER leader Karim Mikhail said the “adapted pathway” i…biospace · 15d ago
- Most new drugs are still too costly at launch, ICER saysA new analysis from the non-profit group found that net launch prices for new medicines spiked significantly between 2022 and 2025, and the majority were well above its cost-effectiveness guidelines.biopharma_dive · 27d ago
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that